Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03174522
Recruitment Status : Terminated (Independent Data Monitoring Committee recommendation to stop due to futility)
First Posted : June 2, 2017
Last Update Posted : March 16, 2023
Andalusian Network for Design and Translation of Advanced Therapies
Information provided by (Responsible Party):
Ixaka Ltd

Brief Summary:
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5. Minimisation will be used to assign eligible subjects in a 2:1 ratio to receive a single intra-arterial administration of REX-001 or matching placebo into the index limb.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease (PAD) Diabetes Mellitus (DM) Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Cardiovascular Disease Critical Limb Ischemia (CLI) Drug: REX-001 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial
Actual Study Start Date : April 25, 2017
Actual Primary Completion Date : February 13, 2023
Actual Study Completion Date : February 13, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: REX-001
REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
Drug: REX-001
REX-001 is administered through an intra-arterial catheter.

Placebo Comparator: Placebo
The final formulation of the placebo will be a diluted suspension of red blood cells.
Drug: Placebo
Placebo is administered through an intra-arterial catheter.

Primary Outcome Measures :
  1. Complete healing of all ischemic ulcers on the index leg. [ Time Frame: The primary endpoint for this trial will be assessed at 12 months. ]
    Change in Rutherford classification from CLI Category 5 to Category 4 or lower 12 months. after administration of REX-001 or placebo.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Aged ≥ 18 to ≤ 85 years.
  2. Diagnosis of Type I or II DM, established more than one year ago.
  3. Glycosylated hemoglobin (HbA1c) < 9%.
  4. Subjects with poor or no (surgical or endovascular) revascularization option classified as CLI Rutherford Category 5. For these patients, one of the following must be confirmed and documented at screening:

    • Ankle systolic pressure < 70 mmHg, or
    • Toe systolic pressure < 50 mmHg, or
    • TcpO2 < 30 mmHg (lying down). Subjects with non-compressible or calcified vessels must qualify on toe pressure or tcpO2.

    Poor or no revascularization option means that, in the opinion of the Investigator, revascularization using surgical or endovascular methods are not feasible due to for example the anatomy of existing vessels and/or existing comorbidity and/or previously failed surgical or endovascular revascularization.

  5. In the opinion of the Investigator, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance) and pain management is optimized.
  6. Women of childbearing potential must have a negative pregnancy test at screening. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Men and women who are sexually active shall use effective contraceptive methods for the duration of their participation in this study if the partner of the male participant, or if the female participant is of childbearing potential. Effective contraceptive methods are e.g.:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal),
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable),
    • Intrauterine device (IUD),
    • Intrauterine hormone-releasing system (IUS),
    • Bilateral tubal occlusion,
    • Vasectomised partner, or
    • Sexual abstinence. The use of this contraceptive method should be continued for at least the duration of participation in the study, and should be continued thereafter as long as indicated by the study doctor.


Subjects meeting any of the following criteria must not be enrolled in the trial:

  1. Advanced CLI defined as presence of major tissue loss as significant ulceration/gangrene proximal to the metatarsal heads (CLI Rutherford Category 6). Significant ulceration/gangrene means any ulceration that extends beyond the subcutaneous tissue layer, or any gangrene or tissue necrosis proximal to the metatarsal heads.
  2. CLI Rutherford Category 4.
  3. Uncontrolled or untreated proliferative retinopathy.
  4. Failed surgical or endovascular revascularization on the index leg within 10 days after the procedure.
  5. Subjects in whom arterial insufficiency in the lower extremity is the result of acute limb ischemia or an immunological or inflammatory or non-atherosclerotic disorder (e.g., thromboangiitis obliterans (Buerger's Disease), systemic sclerosis (both limited and diffuse forms).
  6. Clinical evidence of invasive infection on index leg defined as major tissue loss at the mid-foot or heel involving tendon and/or bone, and/or when intravenous antibiotics are required to treat the infection according to the Investigator.
  7. At screening, the presence of only neuropathic ulcers on the index leg.
  8. Amputation at or above the talus on the index leg.
  9. Planned major amputation within the first month after randomization.
  10. On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new, nonstandard-of-care treatments to the index leg during the trial.
  11. Blood clotting disorder not caused by medication (e.g., thrombophilia).
  12. Severe hypertension according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. (34)
  13. A platelet count < 50,000/μL.
  14. International normalized ratio (INR) > 1.5. For patients on anticoagulant medication an INR > 1.5 is allowed, provided that the Investigator and the haematologist consider the patient eligible to collect BM.
  15. Evidence of moderate to severe hepatocellular dysfunction according to the treating physician.
  16. Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema pallidum.
  17. Subjects who may not be healthy enough to successfully complete all protocol requirements including BM collection, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess, as assessed by the Investigator. For example:

    1. Concurrent severe congestive heart failure (New York Heart Association Classes III and IV).
    2. Life-threatening ventricular arrhythmias, unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged duration), and/or myocardial infarction within four weeks before screening.
    3. Coronary artery bypass grafting or percutaneous coronary intervention within one month before screening.
    4. A renal and/or carotid revascularization procedure within one month of screening.
    5. Transient ischemic attack within three months prior to screening.
    6. Deep vein thrombosis within three months prior to screening.
    7. Subjects with immunocompromised conditions, organ transplant recipients and/or subjects in need of immunosuppressive therapy.
    8. Neurological dementia (i.e., Alzheimer's Disease).
  18. Subjects who participate in another clinical interventional trial.
  19. Subjects who have been treated with experimental medication within 30 days of screening.
  20. Subjects who participated in other cell therapy trials for CLI.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03174522

Layout table for location information
Fakultní nemocnice Ostrava
Ostrava, Czechia
Pécsi Tudományegyetem, PTE-KK I. sz Belgyógyászati Klinika
Pécs, Hungary
Leids Universitair Medisch Centrum
Leiden, Netherlands
Maastricht Universitair Medisch Centrum
Maastricht, Netherlands
Hospital Garcia de Orta, EPE
Almada, Portugal
Centro Hospitalar Lisboa Norte, EPE
Lisboa, Portugal
Centro Hospitalar de São João
Porto, Portugal
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Universitari de Bellvitge
L'Hospitalet De Llobregat, Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Puerta del Mar
Cadiz, Spain
First site: Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital General Universitario Morales Meseguer
Murcia, Spain
Hospital Regional Universitario
Málaga, Spain
United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Sponsors and Collaborators
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies
Layout table for investigator information
Study Director: Gilbert Wagener, MD Ixaka Limited
Layout table for additonal information
Responsible Party: Ixaka Ltd Identifier: NCT03174522    
Other Study ID Numbers: REX-001-005
First Posted: June 2, 2017    Key Record Dates
Last Update Posted: March 16, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Ixaka Ltd:
Bone Marrow-derived Mononuclear Cells (BM-MNCs)
Advanced Therapy Medicinal Product (ATMP)
Tissue-engineered Medicinal Product
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Chronic Limb-Threatening Ischemia
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Autoimmune Diseases
Immune System Diseases
Chronic Disease
Disease Attributes